• On May 7, 2026, Angelini Pharma agreed to acquire Catalyst Pharmaceuticals for $3.9b in cash.
• The deal moves NasdaqCM:CPRX from takeover speculation to a definitive acquisition agreement.
• The transaction is subject to shareholder and regulatory approvals before closing.

Catalyst Pharmaceuticals, trading on NasdaqCM:CPRX, is now at the center of a $3.9b all cash takeover agreement that sets a clear reference point for the stock. With a last close of $30.52 and a value score of 4, the company enters this phase after strong recent share price performance, including a 22.2% return over the past 30 days and 31.8% year to date. Returns over 3 and 5 years have also been very large, which frames how investors may look at the agreed deal value.

For shareholders, the focus from here turns to deal terms, timing, and closing risks, rather than day to day trading moves. As regulatory reviews progress and the shareholder vote approaches, price action in NasdaqCM:CPRX may increasingly reflect expectations about completion and any potential changes to the agreed terms.

Stay updated on the most important news stories for Catalyst Pharmaceuticals by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Catalyst Pharmaceuticals.

The confirmed $3.9b all cash acquisition at $31.50 per share effectively caps near term upside for Catalyst Pharmaceuticals and shifts the focus to deal certainty. The price sits only modestly above the recent close of $30.52, so the key question for you as a shareholder is whether the agreed premium fairly reflects control of a rare disease portfolio that previously attracted strong M&A speculation. The participation of Blackstone funds and BNP Paribas as Sole Global Coordinator for the financing suggests Angelini Pharma has lined up both equity partners and debt capacity, which can matter for confidence in completion. At the same time, the deal still depends on Catalyst stockholder approval and regulatory clearances, so there is conditionality. In the biotech space, peers such as BioMarin, Vertex Pharmaceuticals and Alexion, now part of AstraZeneca, have also been targets or acquirers, and this transaction places Catalyst within that pattern of larger groups seeking established rare disease assets and US commercial infrastructure.

How This Fits Into The Catalyst Pharmaceuticals Narrative

• The agreed acquisition supports the narrative that Catalyst’s rare disease portfolio and commercial platform are attractive to larger pharmaceutical groups seeking established, cash generative assets.
• It challenges the narrative of Catalyst as an independent, cash flow funded acquirer of new products, because the focus now shifts from long term standalone growth to a finite cash exit at $31.50 per share.
• The existing narrative around diagnosis expansion, product mix and patent risk does not fully incorporate deal specific issues such as regulatory approval risk, timing to closing and the absence of any competing bids so far.

Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Catalyst Pharmaceuticals to help decide what it's worth to you.

The Risks and Rewards Investors Should Consider

• ⚠️ There is deal risk, because completion still depends on Catalyst stockholder approval, regulatory clearances and customary conditions, so there is no guarantee the transaction closes as announced.
• ⚠️ The agreed cash price of $31.50 per share may limit further upside if no competing bidders emerge, which can create opportunity cost for investors who expected a higher control premium.
• 🎁 A fully financed, board approved all cash offer backed by Angelini Pharma, Blackstone funds and BNP Paribas provides clarity on value and removes uncertainty about longer term execution as an independent company.
• 🎁 If the deal closes as planned in the third quarter of 2026, shareholders gain a defined timeline for monetizing their investment instead of relying on future market sentiment around drug launches, litigation outcomes or M&A speculation.

What To Watch Going Forward

From here, the key items to watch are any updates on the regulatory review process, the timing and outcome of the Catalyst stockholder vote, and whether any alternative proposals or revised terms are announced before closing. Investors should also pay attention to disclosures in upcoming earnings calls and filings that clarify potential termination scenarios or break fees if conditions are not met.

To ensure you're always in the loop on how the latest news impacts the investment narrative for Catalyst Pharmaceuticals, head to the community page for Catalyst Pharmaceuticals to never miss an update on the top community narratives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.